These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23067211)

  • 41. Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.
    Nawrocki S; Krzakowski M; Wasilewska-Tesluk E; Kowalski D; Rucinska M; Dziadziuszko R; Sowa A
    J Thorac Oncol; 2010 Aug; 5(8):1255-62. PubMed ID: 20592630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
    Standfield L; Weston AR; Barraclough H; Van Kooten M; Pavlakis N
    Respirology; 2011 Nov; 16(8):1210-20. PubMed ID: 21801275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
    Ouyang WW; Su SF; Ma Z; Hu YX; Lu B; Li QS; Geng YC; Li HQ
    Radiat Oncol; 2014 Jun; 9():147. PubMed ID: 24962716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effects of fire needle on quality of life in patients with chemotherapy of non-small cell lung cancer].
    Pei W; Lin S; Zeng J; Qian G; Lin L; Lin G
    Zhongguo Zhen Jiu; 2017 Nov; 37(11):1191-5. PubMed ID: 29354957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
    Rosati G; Rossi A; Nicolella G; Panza N
    Anticancer Res; 2000; 20(3B):2229-33. PubMed ID: 10928183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.
    Li BS; Gong HY; Huang W; Yi Y; Yu JM; Wang ZT; Zhang ZC; Sun HF; Li HS; Wang LY
    Am J Clin Oncol; 2012 Apr; 35(2):115-9. PubMed ID: 21555933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
    Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
    Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
    Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
    Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perspectives on salvage therapy for non-small-cell lung cancer.
    Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
    Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
    Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer.
    Li Q; Jiang M; Han X; Yang Z; Shu W; Ding X
    J Cancer Res Ther; 2020; 16(2):222-229. PubMed ID: 32474505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
    Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
    Sun JM; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Lee JS; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2010 Jun; 68(3):427-32. PubMed ID: 19674811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 60. Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer.
    Ertan E; Soydinc H; Yazar A; Ustuner Z; Tas F; Yasasever V
    Tumori; 2011; 97(3):286-9. PubMed ID: 21789004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.